Avacta Group plc ( (GB:AVCT) ) has issued an announcement.
Avacta Therapeutics announced its participation in the 2025 Leerink Global Healthcare Conference, where it will present its advancements in peptide drug conjugates targeting tumors. This presentation underscores Avacta’s commitment to enhancing its industry positioning by showcasing its innovative cancer therapy solutions, potentially impacting stakeholders by highlighting the company’s strategic focus on tumor-specific treatments.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on developing next-generation peptide drug conjugates (PDC) targeting anti-tumor payloads directly to tumors. The company utilizes its proprietary pre|CISION® platform, which employs a tumor-specific protease to deliver potent cancer therapies while minimizing effects on healthy tissues.
YTD Price Performance: -27.00%
Average Trading Volume: 1,665,155
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £136.1M
Find detailed analytics on AVCT stock on TipRanks’ Stock Analysis page.